Japan’s Best-Selling Chondroitin Sulfate is Now Available for North and South American Markets
Date: May 28, 2014
Source: Zeria USA, Inc.
Zeria USA, Inc., a subsidiary of Zeria Pharmaceutical Co. Ltd., proudly announces that their premier pharmaceutical grade bulk Sodium Chondroitin Sulfate manufactured by ZPD A/S is now available for North and South American markets. ZPD’s Chondroitin Sulfate product has been Japan’s most trusted and best selling consumer Chondroitin brand for over 50 years.
Zeria USA, Inc. announces that ZPD’s pharmaceutical grade bulk Sodium Chondroitin Sulfate is now available for North and South American markets.
Zeria’s Bulk Chondroitin Sulfate is produced at its Danish plant, ZPD A/S (http://www.zpd.dk). Chondroitin Sulfate, sold as a dietary supplement in the US and as an over-the-counter drug in most other countries, is used in formulations for the multi-billion dollar joint health category.
“With aging global populations, demand for products with proven efficacy in the joint health category has spiked. Consumers are looking for proven safe and effective remedies. Our product meets the needs of global consumers and has been the best selling consumer brand in Japan for more than 50 years,” said Kohei Morooka, Zeria USA, Inc.
ZPD’s president, Hiroyasu Nishioka, commented, “the raw material used to produce our bulk Chondroitin Sulfate at ZPD A/S in Denmark is strictly traceable under Danish authority regulation. Importantly, no chemical solvents are used and our product meets California’s Proposition 65 rigorous requirements for safety. Our Chondroitin Sulfate product is manufactured for global markets employing stringent Pharmaceutical manufacturing processes, meeting major International Pharmacopeia standards, including USP, EP and JPC.” Zeria’s proprietary Clinical Study, “Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study”, conducted by Fujita Health University in Japan, supports Zeria’s claims for product efficacy and safety.
“Maintaining the integrity and consistency of the pharmaceutical manufacturing process is integral to product quality,” said Randy J. Dennin, CEO of Randy Dennin & Associates and a former Pfizer Vice President. He went on to comment, “Companies like Zeria Group, with a consistent history of producing safe and effective products according to prescribed pharmaceutical standards, are the much-sought-after partners for the premier supplement formulators in North and South America.”
Zeria USA, Inc. in White Plains, NY is responsible for the distribution of Chondroitin Sulfate manufactured by ZPD A/S for clients in North and South America.
For additional product information, including clinical study results, please contact us at email@example.com.
About Zeria Group
Zeria USA was established in 1989 in NY. Zeria USA, Inc. is a wholly owned subsidiary of Zeria Pharmaceutical Co., Ltd., with headquarters in Tokyo Japan. Since 1955, Zeria Pharmaceutical Co., Ltd. has produced Pharmaceutical and Nutritional products utilizing the highest quality raw materials and pharmaceutical manufacturing standards. Zeria Pharmaceutical Co., Ltd. produces the #1 selling consumer Chondroitin brand, Chondroitin ZS Tablets, and many other products containing Chondroitin for the Japanese market
About ZPD A/S
ZPD A/S, a wholly owned subsidiary of Zeria Pharmaceutical Co., Ltd., manufactures high-quality Sodium Chondroitin Sulfate using a unique proprietary production technology and supplies this product to Japan, Europe and other countries.
Name: Tina Escalona, CCI, Inc.